Pericarditis Market Research Report – Global Forecast till 2030

Pericarditis Market: By Type (Acute Pericarditis, Chronic Pericarditis and Recurrent Pericarditis), By Diagnosis and Treatment [Diagnosis (Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (CT), and X-Ray), Treatment (Medication and Surgical Treatment)], By End User (Hospitals and Clinics, Medical Institutes, Research Organizations and Others) and By Region - Global Forecast Till 2030

ID: MRFR/HC/5746-CR | January 2019 | Region: Global | 156 Pages         

Pericarditis Market Snapshot

MRFR’s study projects a strong growth for the pericarditis market is projected to reach USD 2125.31 Million by 2030 at 5.1% CAGR during the forecast period 2022-2030. Growing prevalence of cardiac disorders worldwide and improving healthcare infrastructure in emerging economies creating opportunities for market players. Americas continues to be the key investment destination for drug companies, with countries such as the U.S., Canada, Mexico and Brazil occupying the leading spots. On a global level, the pericarditis market stood at a valuation of USD 1,750.38 Mn in 2017. Opportunities are likely to get better in emerging markets such as China and India in the forthcoming years. Rising healthcare spending and increased healthcare penetration is providing an impetus to the market in these countries.


This MRFR study presents a holistic viewpoint of the pericarditis market. A revenue forecast for five-years (2018-2023) is also included in the study. It thoroughly discusses all the elements that may have some sort of impact on the pericarditis market during the assessment period. The scope of the discussion also covers different types of pericarditis such as acute pericarditis, chronic pericarditis and recurrent pericarditis. In addition, study shed a light on diagnosis and treatment options available.

Companies Covered

Novartis International AG, Pfizer Inc., AstraZeneca Plc., PerkinElmer, Inc., Sanofi, Johnson & Johnson Services, Inc., Reckitt Benckiser Group Plc, FUJIFILM Holdings Corporation, Bayer AG, Merck & Co., Inc. and Allergan plc.

The pericarditis market report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report.

Research Methodology

MRFR relies on a robust research model for conducting industry analysis. The analysis pattern may differ from sector to sector, but the fundamental structure remains unshaken. Emphasis is placed on maintaining a deep-diving research dogma. For this, interviews and meetings are conducted with opinion holders, thought leaders, and key executives. Also, data is collected from secondary research materials such as SEC filings, dossiers, paid database services, annual report published by industry leaders, etc. The gathered data undergoes a multi-level evaluation process making it error-free. In addition, both top-down and bottom-up approaches are applied to add value to research findings.

Pericarditis Market, By Type

  • Acute Pericarditis

  • Chronic Pericarditis

  • Recurrent Pericarditis

Pericarditis Market, By Diagnosis and Treatment

  • Diagnosis

    • Electrocardiogram (ECG)

    • Echocardiogram

    • Computerized tomography (CT)

    • X-Ray

  • Treatment

    • Medication

    • Surgical treatment

Pericarditis Market, By End User

  • Hospitals and Clinics

  • Medical institutes

  • Research organizations

  • Others

Pericarditis Market, By Region

  • North America

  • Europe

  • Asia Pacific

  • The Middle East & Africa (MEA)

  • Latin America

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Pericarditis market is projected to grow at a 5.1% CAGR between 2022-2030.

Pericarditis market is predicted to touch USD 2125.31 Million by 2030.

The Americas is expected to lead the Pericarditis market.

Favorable reimbursement and the advent of robot-assisted cardiac surgeries are the key factors driving the Pericarditis market.

Certain side effects may limit the Pericarditis market.